| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_001fd829e00a68d4b957cb8c0a5f3a9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39c3a06706e79b48ef4d7b444ec7faaf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2003-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e1edb0cebe70c214cd8b21f747f949b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9f70d8142d88b370aafd6dee2566800 |
| publicationDate |
2005-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1496118-A1 |
| titleOfInvention |
Method of measuring human cyp3a inducibility |
| abstract |
A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. <??>The present invention ensures convenient and accurate evaluation of human CYP3A inducibility upon administration of a test drug to a human subject, providing accurate evaluation in terms of the efficacy of the test drug, occurence of side effects, disappearance of the drug effect, etc. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8624079-B2 |
| priorityDate |
2002-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |